<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04048252</url>
  </required_header>
  <id_info>
    <org_study_id>LOCAL/2019/NH-02</org_study_id>
    <nct_id>NCT04048252</nct_id>
  </id_info>
  <brief_title>Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy</brief_title>
  <acronym>PROSTED</acronym>
  <official_title>Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy: Construction and Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The development of a personalized therapeutic education program dedicated to patients with
      metastatic prostate cancer and receiving next-generation hormone therapy would improve their
      knowledge of the disease, medication adherence and quality of life.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2019</start_date>
  <completion_date type="Anticipated">March 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Create a focus group</measure>
    <time_frame>Day 0</time_frame>
    <description>Transcribe interview and mark key points</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>End of workshops (max 2 months)</time_frame>
    <description>Yes/no</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Successful running of workshop</measure>
    <time_frame>End of workshops (max 2 months)</time_frame>
    <description>Yes/no evaluated by the workshop leader</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient participation rate in workshops</measure>
    <time_frame>End of workshops (max 2 months)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported acceptability of programme</measure>
    <time_frame>End of workshops (max 2 months)</time_frame>
    <description>In-house questionnaire: 4 questions on 0-5 scale unacceptable to very acceptable and 4 open questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported satisfaction of programme</measure>
    <time_frame>End of workshops (max 2 months)</time_frame>
    <description>In-house questionnaire: 5 questions on 0-5 scale unsatisfied to very satisfied</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient knowledge of their disease</measure>
    <time_frame>End of workshops (max 2 months)</time_frame>
    <description>In-house quiz: 7 multiple-choice questions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life</measure>
    <time_frame>1 month after last workshop</time_frame>
    <description>EQ-5D-3L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient medication adherence</measure>
    <time_frame>End of workshops (max 2 months)</time_frame>
    <description>MMAS-9 questionnaire: good adherence is score = 8</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Focus group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Workshop</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Focus group creation</intervention_name>
    <description>Patients will join with researchers for a 2 hour recorded group discussion to highlight themes identified to require educational intervention</description>
    <arm_group_label>Focus group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Workshop</intervention_name>
    <description>Patients will attend 3-4 workshops on eg disease knowledge, medication management and side effects, adapted physical activity and nutrition</description>
    <arm_group_label>Workshop</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with metastatic prostate cancer and receiving next-generation hormone therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with metastatic prostate cancer treated with enzalutamide or abiraterone
             acetate for at least 3 months

          -  The patient must have given their free and informed consent and signed the consent
             form

          -  The patient must be insured or the beneficiary of an insurance policy

        Exclusion Criteria:

          -  The subject is not in a fit state to express their consent

          -  It is impossible to give the subject informed information

          -  The patient is under safeguard of justice or state guardianship
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nadine Houede</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Nimes</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nadine Houede</last_name>
    <phone>04.66.68.33.01</phone>
    <email>nadine.houede@chu-nimes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Nimes</name>
      <address>
        <city>Nîmes</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Anissa Megzari</last_name>
      <phone>04.66.68.42.36</phone>
      <email>drc@chu-nimes.fr</email>
    </contact>
    <investigator>
      <last_name>Nadine Houede</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alice Cuenant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 6, 2019</study_first_submitted>
  <study_first_submitted_qc>August 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

